The authors of the study reported that the analysis of clinical samples revealed that the expression of the fructose transporter proteins GLUT5 and GLUT9 was upregulated in patients with prostate cancer, and that their serum fructose levels were higher than those in normal subjects. This evidence concerns the gene SLC2A5 and prostate cancer.